2016 Press Releases

November 08, 2016FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update
November 01, 2016FibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016
October 31, 2016FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China
August 08, 2016FibroGen Reports Financial Results for the Second Quarter of 2016
August 02, 2016FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
July 25, 2016Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
July 08, 2016FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
June 09, 2016FibroGen Announces Initiation by Astellas of Phase 3 Clinical Study in Japan of Roxadustat/ASP1517 for the Treatment of Anemia of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment
June 06, 2016FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
May 09, 2016FibroGen Reports Financial Results for the First Quarter of 2016
May 02, 2016FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016
April 20, 2016Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis
March 11, 2016FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis
February 29, 2016FibroGen Announces Fiscal 2015 Financial Results
February 19, 2016FibroGen to Report Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
February 16, 2016FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease
January 27, 2016FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer
January 06, 2016FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy